106 related articles for article (PubMed ID: 15596923)
1. Does stereotactic eligibility for the treatment of glioblastoma cause selection bias in randomized studies?
Lustig RA; Scott CB; Curran WJ
Am J Clin Oncol; 2004 Oct; 27(5):516-21. PubMed ID: 15596923
[TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol.
Souhami L; Seiferheld W; Brachman D; Podgorsak EB; Werner-Wasik M; Lustig R; Schultz CJ; Sause W; Okunieff P; Buckner J; Zamorano L; Mehta MP; Curran WJ
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):853-60. PubMed ID: 15465203
[TBL] [Abstract][Full Text] [Related]
3. Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients.
Coughlin C; Scott C; Langer C; Coia L; Curran W; Rubin P
Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1351-8. PubMed ID: 11121633
[TBL] [Abstract][Full Text] [Related]
4. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic radiosurgery versus fractionated stereotactic radiotherapy boost for patients with glioblastoma multiforme.
Cho KH; Hall WA; Lo SS; Dusenbery KE
Technol Cancer Res Treat; 2004 Feb; 3(1):41-9. PubMed ID: 14750892
[TBL] [Abstract][Full Text] [Related]
6. Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience.
Ciammella P; Galeandro M; D'Abbiero N; Podgornii A; Pisanello A; Botti A; Cagni E; Iori M; Iotti C
Clin Neurol Neurosurg; 2013 Sep; 115(9):1609-14. PubMed ID: 23453151
[TBL] [Abstract][Full Text] [Related]
7. Lack of survival benefit after stereotactic radiosurgery boost for glioblastoma multiforme: randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of radiation therapy oncology group 93-05 protocol: in regard to Souhami et al. (Int J Radiat Oncol Biol Phys 2004;60:853-860).
Vordermark D; Kölbl O
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):296-7; author reply 297. PubMed ID: 15850943
[No Abstract] [Full Text] [Related]
8. Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: a report of Radiation Therapy Oncology Group 83-02.
Curran WJ; Scott CB; Weinstein AS; Martin LA; Nelson JS; Phillips TL; Murray K; Fischbach AJ; Yakar D; Schwade JG
J Clin Oncol; 1993 May; 11(5):857-62. PubMed ID: 8487050
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic radiosurgery eligibility and selection bias in the treatment of glioblastoma multiforme.
Anker CJ; Hymas RV; Hazard LJ; Boucher KM; Jensen RL; Shrieve DC
J Neurooncol; 2010 Jun; 98(2):253-63. PubMed ID: 20383558
[TBL] [Abstract][Full Text] [Related]
10. Gamma knife stereotactic radiosurgery for patients with glioblastoma multiforme.
Nwokedi EC; DiBiase SJ; Jabbour S; Herman J; Amin P; Chin LS
Neurosurgery; 2002 Jan; 50(1):41-6; discussion 46-7. PubMed ID: 11844233
[TBL] [Abstract][Full Text] [Related]
11. Survival following CyberKnife radiosurgery and hypofractionated radiotherapy for newly diagnosed glioblastoma multiforme.
Lipani JD; Jackson PS; Soltys SG; Sato K; Adler JR
Technol Cancer Res Treat; 2008 Jun; 7(3):249-55. PubMed ID: 18473497
[TBL] [Abstract][Full Text] [Related]
12. Measuring bias in uncontrolled brain tumor trials--to randomize or not to randomize?
Irish WD; Macdonald DR; Cairncross JG
Can J Neurol Sci; 1997 Nov; 24(4):307-12. PubMed ID: 9398977
[TBL] [Abstract][Full Text] [Related]
13. Implant volume as a prognostic variable in brachytherapy decision-making for malignant gliomas stratified by the RTOG recursive partitioning analysis.
Videtic GM; Gaspar LE; Zamorano L; Stitt LW; Fontanesi J; Levin KJ
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):963-8. PubMed ID: 11704318
[TBL] [Abstract][Full Text] [Related]
14. Application of recursive partitioning analysis and evaluation of the use of whole brain radiation among patients treated with stereotactic radiosurgery for newly diagnosed brain metastases.
Chidel MA; Suh JH; Reddy CA; Chao ST; Lundbeck MF; Barnett GH
Int J Radiat Oncol Biol Phys; 2000 Jul; 47(4):993-9. PubMed ID: 10863070
[TBL] [Abstract][Full Text] [Related]
15. Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials.
Buckner JC; Ballman KV; Michalak JC; Burton GV; Cascino TL; Schomberg PJ; Hawkins RB; Scheithauer BW; Sandler HM; Marks RS; O'Fallon JR; ;
J Clin Oncol; 2006 Aug; 24(24):3871-9. PubMed ID: 16921039
[TBL] [Abstract][Full Text] [Related]
16. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases.
Frakes JM; Figura NB; Ahmed KA; Juan TH; Patel N; Latifi K; Sarangkasiri S; Strom TJ; Chinnaiyan P; Rao NG; Etame AB
J Neurosurg; 2015 Nov; 123(5):1261-7. PubMed ID: 26140482
[TBL] [Abstract][Full Text] [Related]
17. Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme.
Del Rowe J; Scott C; Werner-Wasik M; Bahary JP; Curran WJ; Urtasun RC; Fisher B
J Clin Oncol; 2000 Mar; 18(6):1254-9. PubMed ID: 10715295
[TBL] [Abstract][Full Text] [Related]
18. Treatment outcomes for patients with glioblastoma multiforme and a low Karnofsky Performance Scale score on presentation to a tertiary care institution. Clinical article.
Marina O; Suh JH; Reddy CA; Barnett GH; Vogelbaum MA; Peereboom DM; Stevens GH; Elinzano H; Chao ST
J Neurosurg; 2011 Aug; 115(2):220-9. PubMed ID: 21548745
[TBL] [Abstract][Full Text] [Related]
19. High-dose-rate stereotactic brachytherapy for patients with newly diagnosed glioblastoma multiformes.
Chang CN; Chen WC; Wei KC; Ng SH; Ho YS; Huang DY; Lee SP; Hong JH
J Neurooncol; 2003 Jan; 61(1):45-55. PubMed ID: 12587795
[TBL] [Abstract][Full Text] [Related]
20. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.
Mirimanoff RO; Gorlia T; Mason W; Van den Bent MJ; Kortmann RD; Fisher B; Reni M; Brandes AA; Curschmann J; Villa S; Cairncross G; Allgeier A; Lacombe D; Stupp R
J Clin Oncol; 2006 Jun; 24(16):2563-9. PubMed ID: 16735709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
